Exalys Therapeutics is developing a portfolio of novel anti-inflammatory therapeutics with best-in-class properties to target a range of diseases with urgent unmet needs and limited treatment options.

Exalys is initially targeting postoperative delirium, the most common complication of surgery in older patients and a key driver of poor health outcomes.

The Exalys portfolio of product candidates has the potential to be applied to a number of other acute and chronic disease states with high societal impacts.